These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 31211144)

  • 21. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
    Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
    Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
    Bunchorntavakul C; Buranathawornsom A
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3308-3313. PubMed ID: 34622504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vonoprazan-amoxicillin dual therapy for
    Zhou BG; Mei YZ; Jiang X; Zheng AJ; Ding YB
    Saudi J Gastroenterol; 2023; 29(6):347-357. PubMed ID: 37602635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials.
    Zhang M; Pang M; Zhang M
    Clinics (Sao Paulo); 2022; 77():100058. PubMed ID: 35810638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection.
    Shinmura T; Adachi K; Yamaguchi Y; Izawa S; Hijikata Y; Ebi M; Funaki Y; Ogasawara N; Sasaki M; Kasugai K
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):389-395. PubMed ID: 31826057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kobayashi Y; Miura Y; Lefor AK; Yamamoto H
    Kaohsiung J Med Sci; 2018 Aug; 34(8):456-460. PubMed ID: 30041763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vonoprazan: A Review in Helicobacter pylori Infection.
    Shirley M
    Drugs; 2024 Mar; 84(3):319-327. PubMed ID: 38388872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
    Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
    Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
    Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T
    Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
    Ju KP; Kong QZ; Li YY; Li YQ
    Helicobacter; 2024; 29(1):e13054. PubMed ID: 38900537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
    Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
    Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
    Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
    Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
    Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
    J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis.
    Deguchi H; Yamazaki H; Kamitani T; Yamamoto Y; Fukuhara S
    Adv Ther; 2021 Jul; 38(7):3937-3947. PubMed ID: 34091865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication.
    Horii T; Suzuki S; Takano C; Shibuya H; Ichijima R; Kusano C; Ikehara H; Gotoda T
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3314-3321. PubMed ID: 34107551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y; Shimoyama T; Mizuki I
    Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis.
    Feng JH; Cheng J; Lao YJ; Huang K; Mou JL; Hu F; Lin ML; Lin J
    Eur J Med Res; 2023 Aug; 28(1):272. PubMed ID: 37550781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
    Du RC; Hu YX; Ouyang Y; Ling LX; Xu JY; Sa R; Liu XS; Hong JB; Zhu Y; Lu NH; Hu Y
    Helicobacter; 2024; 29(1):e13039. PubMed ID: 38036941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy.
    Yang H; Zhang M; Ma G; Yang J; Wang K; Jiang S; Dong J; Han Y
    Helicobacter; 2024; 29(2):e13059. PubMed ID: 38443329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.